← Leaderboards
Michaela Ann Dinan
Yale University
$4,428,713
Attributed
$5,423,151
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,406,333 · 3
AHRQ$1,016,818 · 2
By mechanism
R01$4,210,266 · 2
R00$745,780 · 1
K99$271,038 · 1
P30$196,067 · 1
Top collaborators
- Cary P Gross3 shared
Most similar at Yale University
Same institution · by research overlap
- David F Stern$15,325,663
- Peter M Glazer$37,467,142
- Melinda L Irwin$13,917,828
- Colleen L Barry$6,067,460
- Douglas L. Leslie$7,297,569
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsSocioeconomic StatusPatient PopulationDiagnosisMedicareComorbidityPatient-Focused OutcomesData SetCostAdoptionInsuranceInsurance CoverageGeographyTreatment OutcomePharmaceutical PreparationsOralPhysiciansAreaCancer PatientAntineoplastic AgentsEducationInvestigationImprove AccessChronic
Grant awards (15)
Broad Genomic Profiling in patients with advanced lung cancer: empirically assessing adoption, clinical utility, and the value of additional evidence in an evolving landscape of cancer care$653,926
R01 · FY2025 · CA
Cancer Research Training and Education Coordination$196,067
P30 · FY2025 · CA · contact PI
Broad Genomic Profiling in patients with advanced lung cancer: empirically assessing adoption, clinical utility, and the value of additional evidence in an evolving landscape of cancer care$628,231
R01 · FY2024 · CA
Broad Genomic Profiling in patients with advanced lung cancer: empirically assessing adoption, clinical utility, and the value of additional evidence in an evolving landscape of cancer care$706,720
R01 · FY2023 · CA
Disparities in the Use of Oral Anticancer Agents in Kidney Cancer$372,756
R01 · FY2023 · CA · contact PI
Disparities in the Use of Oral Anticancer Agents in Kidney Cancer$378,662
R01 · FY2022 · CA · contact PI
Disparities in the Use of Oral Anticancer Agents in Kidney Cancer$402,093
R01 · FY2021 · CA · contact PI
Disparities in the Use of Oral Anticancer Agents in Kidney Cancer$367,546
R01 · FY2020 · CA · contact PI
Investigation of the bidirectional relationship between kidney cancer treatment and dementia$320,400
R01 · FY2020 · CA · contact PI
Disparities in the Use of Oral Anticancer Agents in Kidney Cancer$379,932
R01 · FY2019 · CA · contact PI
National Utilization Patterns of Oncotype DX in Early Stage Breast Cancer$248,878
R00 · FY2017 · HS · contact PI
National Utilization Patterns of Oncotype DX in Early Stage Breast Cancer$247,902
R00 · FY2016 · HS · contact PI
National Utilization Patterns of Oncotype DX in Early Stage Breast Cancer$249,000
R00 · FY2015 · HS · contact PI
National Utilization Patterns of Oncotype DX in Early Stage Breast Cancer$135,827
K99 · FY2014 · HS · contact PI
National Utilization Patterns of Oncotype DX in Early Stage Breast Cancer$135,211
K99 · FY2013 · HS · contact PI